Cytosorbents Corporation

Equities

CTSO

US23283X2062

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 03:41:04 2024-05-15 pm EDT			5-day change	1st Jan Change
0.815 ^USD	-2.00%		-5.95%	-26.13%

May. 09	Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M	MT
May. 09	Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

January 23, 2023 at 07:02 am EST

CytoSorbents Corporation announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.

Latest news about Cytosorbents Corporation

Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M	May. 09	MT
Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024	May. 09
Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Transcript : Cytosorbents Corporation - Analyst/Investor Day	May. 06
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	Mar. 14	MT
Transcript : Cytosorbents Corporation, Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	Jan. 17	CI
North American Morning Briefing : Stock Futures Struggle After Weak China Data	Jan. 02	DJ
HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50	Dec. 29	MT
S&P 500 ekes out meager gains, flirts with bull market confirmation	Dec. 28	RE
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT
Top Midday Decliners	Dec. 28	MT
Wall St inches higher as S&P 500 flirts with bull market confirmation	Dec. 28	RE
US Stocks Holding on for Small Thursday Gains, Again Drifting Near Record Highs	Dec. 28	MT
US Stocks Adding to Recent Gain Amid New Economic Data	Dec. 28	MT
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating	Dec. 28	MT
US STOCKS -Wall Street edges higher as year end approaches, rate cuts in focus	Dec. 28	RE
Sector Update: Health Care Stocks Steady Premarket Thursday	Dec. 28	MT
Sector Update: Health Care	Dec. 28	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday	Dec. 28	MT
Cytosorbents Says DrugSorb-ATR Study Misses Primary Effectiveness Endpoint; Shares Fall Pre-Bell	Dec. 28	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	Dec. 28	MT
Sector Update: Health Care	Dec. 28	MT
Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation	Dec. 28	CI

Chart Cytosorbents Corporation

Duration

Period

More charts

Company Profile

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Companyâs flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cytosorbents Corporation

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8316 USD

Average target price

2.667 USD

Spread / Average Target

+220.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYTOSORBENTS CORPORATION	-26.13%	45.16M
THERMO FISHER SCIENTIFIC	+12.97%	227B
DANAHER CORPORATION	+13.81%	192B
INTUITIVE SURGICAL, INC.	+18.00%	136B
BOSTON SCIENTIFIC CORPORATION	+28.28%	108B
SIEMENS HEALTHINEERS AG	+1.67%	64.07B
EDWARDS LIFESCIENCES CORPORATION	+17.74%	52.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B
AGILENT TECHNOLOGIES, INC.	+10.63%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+5.96%	36.75B

Other Advanced Medical Equipment & Technology